|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Johnson_&_Johnson_COVID-19_Vaccine
gptkb:Ad26.COV2.S
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2021
|
|
gptkbp:contains
|
recombinant, replication-incompetent adenovirus type 26 vector
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:doseRegimen
|
single dose
|
|
gptkbp:emergencyServices
|
granted in multiple countries
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Jcovden
|
|
gptkbp:includedIn
|
gptkb:COVAX_program
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:notRecommendedFor
|
children under 18 in some countries
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
rare blood clotting events
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:WHOEmergencyUseListing
|
2021
|
|
gptkbp:withdrawn
|
United States (2023)
|
|
gptkbp:bfsParent
|
gptkb:Janssen_COVID-19_Vaccine
|
|
gptkbp:bfsLayer
|
7
|